Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
CNS disorders remain the world?s leading cause of disability. Currently, no cures are present, which indicates a high unmet
need for good CNS drugs and drug therapies.
Apart from a drugs physicochemical properties and blood?brain barrier (BBB) transport, the rate an extent of many
processes that govern brain target site kinetics and CNS effects are regulated dynamically. Therefore, heterogeneous conditions
such as species, gender, genetic background, tissue, age, diet, disease, drug treatment, might result in considerable interindividual
and intra-individual variation.
Drugs should access the CNS ?at the right place, at the right time, and at the right concentration?. To improve CNS therapies
and drug development, details of inter-species and inter-condition variations are needed to enable target site pharmacokinetics
and associated CNS effects to be translated between species and between disease states. Studies need to be designed according
to the ?Mastermind approach?. This strategic and systematic CNS drug research approach, using advanced preclinical
experimental designs and mathematical modeling will enable us to identify the contributions and variability of individual
processes on the causal path between drug dosing and CNS effect in animals that can be translated to the human situation.
On the basis of a few advanced preclinical microdialysis based investigations it will be shown that the ?Mastermind
approach? has a high potential for the prediction of human CNS pharmacokinetics and CNS drug effects. Examples will be
shown for acetaminophen, methotrexate and remoxipride.
Biography
Elizabeth C M de Lange has completed her PhD in 1993 and was tenured in 2001 at the Leiden Academic Centre of Drug Research, Leiden University (LACDR),
the Netherlands. She currently is the Acting Head of the Division of Pharmacology of the LACDR. She is also the CEO of the CNS Drug Courses and Consultancy
Company ?In Focus?. She has published over 65 papers in reputed journals, over 10 Book Chapters, co-edited the book ?Drug Delivery to the Brain- Physiological
Concepts, Methodologies and Approaches?. Furthermore she serves at editorial board member of reputed journals.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals